content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                         ----------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 10, 2004
                                                          ------------------
  
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
       Delaware                         000-14879                  22-2322400
  ----------------------------    -----------------------      -------------------
  (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
    650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  --------------------------------------------------------------  ---------------
       (Address of Principal Executive Offices)                       (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to  Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
       On September 10, 2004,  Cytogen  Corporation (the "Company") entered into a
  non-exclusive  Manufacturing  Agreement (the  "Agreement") with Laureate Pharma,
  L.P.   ("Laureate")  for  the  Company's  ProstaScint  product.  All  terms  not
  specifically  defined  herein  shall have the  meaning  ascribed  to them in the
  Agreement.
  
       The Agreement is effective immediately and shall terminate,  unless earlier
  terminated  pursuant to the terms  thereof,  upon  Laureate's  completion of the
  Production  Campaign  and shipment of the  resulting  products  from  Laureate's
  Facility in Princeton,  NJ. It is intended  that the Agreement  will provide the
  Company  with a  sufficient  supply of  ProstaScint  to satisfy  its  commercial
  requirements  for  approximately  the next four years based upon  current  sales
  levels.
  
       The Company  has sought  confidential  treatment  from the  Securities  and
  Exchange  Commission  for  certain  portions  of the  Agreement.  A copy  of the
  redacted  Agreement is attached as Exhibit  10.1 to this Current  Report on Form
  8-K and is incorporated  herein by reference.  The foregoing  description of the
  Agreement is qualified in its entirety by reference to such Exhibit.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
      Exhibit No.       Description
      -----------       -----------
         10.1*          Manufacturing  Agreement  dated September 10, 2004  by and
                        between the Company and Laureate Pharma, L.P.
  
  * The Company has submitted an application for  confidential  treatment with the
  Securities and Exchange Commission with respect to certain provisions  contained
  in this exhibit.  The copy filed as an exhibit omits the information  subject to
  the confidentiality application.
  
  <PAGE>
  
  
                                     SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   September 14, 2004
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
            Exhibit No.       Description
            -----------       -----------
  
               10.1*          Manufacturing  Agreement dated  September 10, 2004
                              by and between the Company and Laureate Pharma, L.P.
  
  * The Company has submitted an application for  confidential  treatment with the
  Securities and Exchange Commission with respect to certain provisions  contained
  in this exhibit.  The copy filed as an exhibit omits the information  subject to
  the confidentiality application.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_91304.txt", "description": "FORM 8-K 09/13/04", "secsgml_size_bytes": 5316}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "041030074"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                         ----------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 10, 2004
                                                          ------------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
       Delaware                         000-14879                  22-2322400
  ----------------------------    -----------------------      -------------------
  (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
    650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  --------------------------------------------------------------  ---------------
       (Address of Principal Executive Offices)                       (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to  Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
       On September 10, 2004,  Cytogen  Corporation (the "Company") entered into a
  non-exclusive  Manufacturing  Agreement (the  "Agreement") with Laureate Pharma,
  L.P.   ("Laureate")  for  the  Company's  ProstaScint  product.  All  terms  not
  specifically  defined  herein  shall have the  meaning  ascribed  to them in the
  Agreement.
  
       The Agreement is effective immediately and shall terminate,  unless earlier
  terminated  pursuant to the terms  thereof,  upon  Laureate's  completion of the
  Production  Campaign  and shipment of the  resulting  products  from  Laureate's
  Facility in Princeton,  NJ. It is intended  that the Agreement  will provide the
  Company  with a  sufficient  supply of  ProstaScint  to satisfy  its  commercial
  requirements  for  approximately  the next four years based upon  current  sales
  levels.
  
       The Company  has sought  confidential  treatment  from the  Securities  and
  Exchange  Commission  for  certain  portions  of the  Agreement.  A copy  of the
  redacted  Agreement is attached as Exhibit  10.1 to this Current  Report on Form
  8-K and is incorporated  herein by reference.  The foregoing  description of the
  Agreement is qualified in its entirety by reference to such Exhibit.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
      Exhibit No.       Description
      -----------       -----------
         10.1*          Manufacturing  Agreement  dated September 10, 2004  by and
                        between the Company and Laureate Pharma, L.P.
  
  * The Company has submitted an application for  confidential  treatment with the
  Securities and Exchange Commission with respect to certain provisions  contained
  in this exhibit.  The copy filed as an exhibit omits the information  subject to
  the confidentiality application.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   September 14, 2004
  EXHIBIT INDEX
  
            Exhibit No.       Description
            -----------       -----------
  
               10.1*          Manufacturing  Agreement dated  September 10, 2004
                              by and between the Company and Laureate Pharma, L.P.
  
  * The Company has submitted an application for  confidential  treatment with the
  Securities and Exchange Commission with respect to certain provisions  contained
  in this exhibit.  The copy filed as an exhibit omits the information  subject to
  the confidentiality application.